Clinical Trial Results:
            A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
    
|     Summary | |
|     EudraCT number | 2008-002983-32 | 
|     Trial protocol | BE ES DE GB FR IT GR | 
|     Global completion date | 
                                    20 Feb 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    15 Dec 2016
                             | 
|     First version publication date | 
                                    15 Dec 2016
                             | 
|     Other versions | |
|     Summary report(s) | CLBH589B2213.CTR.03Nov2016 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
